PanTher Therapeutics has been selected for the prestigious MedTech Innovator 2023 Program in the mid-stage company cohort. Among a competitive pool of ~1,150 company applicants, nearly 200 advanced to the in-person pitch and partnering events on the MedTech Innovator Road Tour. Over 400 industry experts completed four months of diligence, selecting PanTher to be among the 61 startups selected for this cohort.
Laura Indolfi, CEO and Co-Founder of PanTher Therapeutics is featured in the Massachusetts Life Sciences Center’s Series “Women Who Lead in Life Sciences” published in the print edition of the Boston Business Journal. PanTher Therapeutics is developing the next cancer treatment by targeting the disease at its source.
PanTher’s CEO and Founder, Laura Indolfi, joins MedTech Monday podcast host Giovanni Lauricella to discuss angels vs. institutional money, Silicon Valley Bank, pitching to the wrong people, psychology that you must have while raising money, her Ted Talk, and so much more.
PanTher Therapeutics presents “Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma – A Trial in Progress” poster at the American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., The poster highlights the trial-in-progress for the treatment of borderline resectable or locally advanced pancreatic ductal adenocarcinoma ongoing in Australia. PanTher Therapeutics’ CEO Laura Indolfi and study Principal Investigator John Zalcberg are present to answer any questions.
PanTher Therapeutics’ mission of Attacking Cancer at the Source™ is shared from the famous Times Square billboards in New York City November 7-13, 2022. As part of a sponsored campaign with Brex, PanTher displays their mission to the mass of people visiting the major commercial intersection, tourist destination, and entertainment hub that is Times Square.
PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.